"The U.S. Food and Drug Administration today approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children.
Neuroblastoma is a r"...
There is no known antidote for MESNEX.
In a clinical trial, 11 patients received intravenous MESNEX 10 mg/kg to 66 mg/kg per day for 3 to 5 days. Patients also received ifosfamide or cyclophosphamide. Adverse reactions included nausea, vomiting, diarrhea and fever. An increased rate of these adverse reactions has also been found in oxazaphosphorinetreated patients receiving ≥ 80 mg MESNEX per kg per day intravenously compared with patients receiving lower doses or hydration treatment only.
MESNEX is contraindicated in patients known to be hypersensitive to MESNEX or to any of the excipients [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 4/1/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Mesnex Information
Mesnex - User Reviews
Mesnex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.